-
Product Insights
NewNet Present Value Model: PDS Biotechnology Corp’s PDS-0101
Empower your strategies with our Net Present Value Model: PDS Biotechnology Corp's PDS-0101 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Budigalimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Budigalimab in Non-Small Cell Lung Cancer Drug Details: Budigalimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vobramitamab Duocarmazine in Metastatic Castration-Resistant Prostate Cancer...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PDS-01ADC in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PDS-01ADC in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PDS-01ADC in Non-Small Cell Lung Cancer Drug Details: PDS-0301 (M-9241,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanzalintinib Fumarate in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanzalintinib Fumarate in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanzalintinib Fumarate in Laryngeal Cancer Drug Details: Zanzalintinib fumarate (XL-092) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PDS-01ADC in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PDS-01ADC in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PDS-01ADC in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: PDS-0301 (M-9241,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Dedifferentiated Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Dedifferentiated Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Dedifferentiated Liposarcoma Drug Details: Eftilagimod alfa (IMP-321,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Odetiglucan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Odetiglucan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Odetiglucan in...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivarmacitinib Sulfate in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivarmacitinib Sulfate in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivarmacitinib Sulfate in Graft Versus Host Disease...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vas-01 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vas-01 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vas-01 in Gallbladder Cancer Drug Details: Vas-01 (Recombinant fusion protein) is under...